Business Context and Reporting Period
This Form 8-K was filed by Revelation Biosciences, Inc. on February 16, 2023. The report addresses the Company's status regarding its listing on The Nasdaq Stock Market following previous non-compliance notices.
Key Financial Metrics
- Cash Proceeds: Approximately $14.1 million in net cash proceeds from a Public Offering closed on February 13, 2023.
- Stockholders' Equity: The Company has met the minimum requirement of $2.5 million.
- Stock Price: The common stock traded above $1.00 per share for 11 consecutive trading days as of February 15, 2023.
- Other Metrics: The filing does not provide specific values for revenue, profit, operating cash flow, margins, or total debt.
Material Changes
The primary material change is the restoration of compliance with Nasdaq listing standards. Previously, the Company received delisting notices for failing to meet the minimum bid price (Rule 5550(a)(2)) and minimum stockholders' equity (Rule 5550(b)(1)) requirements. The Company has now regained compliance with both standards.
Outlook, Risks, and Management Commentary
Nasdaq has formally notified the Company that its common stock will continue to be listed and traded. The Company had a compliance plan approved by a Nasdaq hearing panel with a deadline of April 18, 2023, which it has now satisfied ahead of schedule. The filing does not contain forward-looking guidance, risk factors, or unusual items beyond the resolution of the listing compliance issue.
Investor Verification Checklist
- Verify the final net cash proceeds from the February 13, 2023 Public Offering.
- Confirm the current stockholders' equity balance exceeds the $2.5 million threshold.
- Monitor the stock price to ensure it remains above the $1.00 minimum bid price requirement.
- Review the Company's cash burn rate to assess the sustainability of the regained equity position.